- Home
- GILD
GILD
Gilead Sciences Inc.
as 05-08-2025 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 129.9B | IPO Year: | 1992 |
| Target Price: | $108.00 | AVG Volume (30 days): | 8.7M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.73 | EPS Growth: | 1118.07 |
| 52 Week Low/High: | $62.07 - $119.96 | Next Earning Date: | 04-24-2025 |
| Revenue: | $28,735,000,000 | Revenue Growth: | 4.68% |
| Revenue Growth (this year): | 1.88% | Revenue Growth (next year): | 3.95% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | GILD | Chief Financial Officer | Apr 15 '25 | Sell | $106.40 | 2,500 | $266,000.00 | 168,174 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Mar 17 '25 | Sell | $110.53 | 2,500 | $276,325.00 | 168,174 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Mar 10 '25 | Sell | $117.90 | 17,929 | $2,118,695.72 | 168,174 | |
| GILEAD SCIENCES, INC. | GILD | 10% Owner | Feb 18 '25 | Buy | $11.00 | 1,363,636 | $14,999,996.00 | 31,424,760 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Feb 18 '25 | Sell | $104.09 | 2,500 | $260,225.00 | 168,174 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Feb 12 '25 | Sell | $102.22 | 137,676 | $14,073,240.72 | 168,174 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
Business Wire
2 days ago
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
ACCESS Newswire
2 days ago
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
MT Newswires
3 days ago
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating
Zacks
3 days ago
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Argus Research
3 days ago
Market Digest: BAX, CAH, CCEP, EPD, EQIX, GILD, MCO, MGM, MSI, RJF, RTX, GM, META, APTV, XYZ
Argus Research
3 days ago
Analyst Report: Gilead Sciences, Inc.
StockStory
4 days ago
1 Profitable Stock on Our Watchlist and 2 to Turn Down
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.